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To the Editor:
The extensive work for a new
classification of lung adenocarcinoma
by Travis et al.1 is highly appreciated.
Nevertheless, new terms and definitions
raise questions and discussions, which
should be addressed in focus of the ap-
plication of the new multidisciplinary
classification of lung adenocarcinoma to
clinical management of patients with
lung cancer worldwide.
First, the inclusion of tumor size
in solitary nodules (3 cm and 5
mm invasion) into the new classifica-
tion is questionable. A continuous de-
velopment of preinvasive lesions into
more extensive disease stages may oc-
cur, independent from the chosen size;
furthermore, size is a prognostic rele-
vant criterion within the existing tumor,
node, metastasis (TNM) system which
should not be replaced. In this context,
the terms adenocarcinoma in situ and
minimally invasive adenocarcinoma
have a potential of misguidance, espe-
cially due to their limitation on resection
specimens, which is not applicable to
small biopsies and cytological speci-
mens as well. Considering the aspect
that also small simultaneous multilocu-
lar lesions may occur, the question
arises, how multilocular synchronous le-
sions could be histologically distin-
guished from a solitary lesion in the
proposed classification. The present
term “bronchioalveolar carcinoma” is
restricted to tumors with lepidic growth,
or at least predominantly lepidic growth,
and does not address size, solitary, or—
synchronous—multiple location, which
is expressed by the TNM formula, thus
offering a clear classificatory descrip-
tion. Therefore, the relation between the
clinical TNM system and the new clas-
sification has to be clarified to avoid an
overlap f.e. in a T1a status according to
the International Association for the
Study of Lung Cancer 2007.2
For pneumologists in particular,
small biopsies are frequently the basis
for diagnosis, and a solution to render
the vague new term “favor” (non-
small cell lung cancer favor adenocar-
cinoma) more precisely could be the
addition of a quality marker for histo-
logical or cytological diagnosis as it is
available in the TNM system for the
clinical use (C1–C4).3 Using such an
adjunct, no artificial separations be-
tween small and large biopsies or new
terms would be necessary.
Christian Witt, MD, PhD
Division of Pneumology
Department of Pneumological Oncology
Charite´ - Medical University Berlin
Berlin, Germany
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Sublobar Resection of
Ground Glass
Opacity—Great Data,
but can I have More?
To the Editor:
I read with great interest the ar-
ticle by Susuki et al.1 and commend
the authors for applying formal scien-
tific methods in a prospective study to
the issue of selection of patients for
sublobar resection. These investigators
and others from Japan have led the
world in better defining the manage-
ment of these patients. Nevertheless, I
wish they had reported a few more
details.
From a statistician’s point of
view, sensitivity and specificity are
good measures, but these do not lend
themselves well to prospective appli-
cation to an individual patient, which
is the problem faced by the clinician.
Specificity tells us how often the ra-
diographic assessment will be positive
for invasion in a cohort of patients in
whom it is already known that they all
have invasion.2 A clinician, of course,
does not know whether the patient has
or does not have invasion preopera-
tively and only knows that the radio-
graphic assessment has been either
negative or positive. Thus, the clini-
cian needs to know how often the
assessment of “radiographically non-
invasive” is falsely negative. This re-
quires knowledge of the false-negative
(FN) rate of the test result (or, as some
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